ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone tuberculosis is characterized by severe bone destruction driven by aberrant osteoclast overactivation. However, the direct mechanism by which Mycobacterium tuberculosis (Mtb) mediates this pathological process remains unclear. Understanding the molecular basis of pathogen-driven osteoclast dysregulation is essential for developing effective host-directed therapeutic strategies. Methods: Transcriptomic profiling was performed to identify differentially expressed sialylation-related genes and activated signaling pathways in Mtb-infected cells. Murine bone-tuberculosis models and in vitro osteoclast cultures were employed to assess osteoclast activity and surface α2,3-sialylation levels following Mtb infection. Functional interventions included enzymatic removal of α2,3-sialic acid and pharmacological inhibition of ST3GAL1. Metabolomic analysis was conducted to characterize Mtb-induced alterations in glycerophospholipid metabolism. Results: Transcriptomic profiling revealed upregulation of sialylation-related genes and activation of TLR2-dependent signaling upon Mtb infection, providing a molecular basis for pathogen-driven surface glycan modifications. In both murine bone-tuberculosis models and in vitro osteoclast cultures, Mtb infection concurrently enhanced osteoclast activity and surface α2,3-sialylation. Enzymatic desialylation or ST3GAL1 inhibition markedly attenuated this overactivation. Metabolomic analysis further demonstrated Mtb-induced reprogramming of glycerophospholipid metabolism, potentially supplying substrates for sialylated glycoconjugate biosynthesis. Discussion: These findings identify α2,3-sialylation as a central driver of Mtb-induced pathological osteoclast activity, mechanistically linking TLR2 signaling, surface glycan remodeling, and metabolic reprogramming. The coordinate regulation of membrane glycoconjugate biosynthesis and glycerophospholipid metabolism suggests an integrated host response exploited by Mtb to promote bone destruction. Collectively, host glycosylation machinery and associated metabolic pathways represent promising targets for host-directed therapy in bone tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.